Imexpharm Corporation · HOSE:IMP
Imexpharm — 10M2024 Earnings Presentation
6 slides from Imexpharm's earnings presentation, November 2024
Slide 1: October and 10M2024 Business Updates
OCTOBER AND 10M2024 BUSINESS UPDATES IMEXPHARM CORPORATION
Slide 2: Sharp increase in EBITDA and PBT fueled by efficient cost management
Sharp increase in EBITDA and PBT fueled by efficient cost management ▪ IMP achieved record-high monthly October net revenue EBITDA and PBT, surging 22% VND 176 bn and 29% year-over-year, respectively, despite a slight dip ▼ 3% YoY in October's net revenue ETC ▲ 41% YoY ▪ SG&A costs were optimized to
Slide 3: Strong revenue propels resilient 10M performance
Strong revenue propels resilient 10M performance 10M net revenue ▪ We have achieved VND 1,729 VND 1,729 bn billion in net revenue, representing 73% of the ▲ 10% YoY ETC ▲ 33% YoY AGM target. ▪ Despite the need to ramp up our newest plant IMP4’s 10M EBITDA utilization rate and a weaker OTC market, IM
Slide 4: Stock performance
Stock performance Data as of 31 Oct 2024 250 % IMP 150 DHG TRA DBD 50 DHT VN-Index -50 29-Dec 29-Jan 29-Feb 31-Mar 30-Apr 31-May 30-Jun 31-Jul 31-Aug 30-Sep 31-Oct IMP DHG TRA DHT DBD YTD avg. daily trading volume 71,831 24,183 2,156 112,039 201,498 YTD stock performance 77% 4% (11%) 210% 14% Daily
Slide 5: Disclaimer
Disclaimer The contents of the IR Newsletter are intended to provide information to institutional investors as well as individual investors of Imexpharm Corporation (Hose: IMP). IMP strives to ensure transparency, completeness, and accuracy of the information in this newsletter. IMP is exempt from a
Slide 6: Thank You
Thank You For further discussion, please contact our IR team ir@imexpharm.com 6